Skip to main content

Table 1 Study characteristics and input data for 20 trials included in the NMA

From: Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis

Study (Source)

Treatment Arms

N

Male

Age, y

Baseline mean CD4+, cells/mL (SD)

Baseline mean viral load, log10 RNA copies/mL, (SD)

N with Virologic Suppression HIV RNA < 50 copies/mL (r/n)

CD4+ change, cells/μL

AEs (r/n)

Drug-related AEs (r/n)

Serious AEs (r/n)

Discontin-uations (r/n)

ACTG A5257 ([15])

ATV/r + TDF/FTC

605

76.20

37

309

4.60a

379/605

280

489/605

89/605

DRV/r + TDF/FTC

601

76.21

37

310

4.61a

437/601

256

390/601

101/601

RAL + TDF/FTC

603

75.46

36

304

4.66a

481/603

288

359/603

72/603

ECHO + THRIVE [16]

EFV + TDF/FTC

546

78.94

36

261a

5.0a

422/546

222

61/546

RPV + TDF/FTC

550

78.00

36

247a

5.0a

423/550

226

52/550

FLAMINGO (CSR) [17]

DRV/r + ABC/3TC

242

83.06

34

400a

4.48a

60/80

274.4 (SD:226.64)

217/242

124/242

21/242

52/242

DRV/r + TDF/FTC

104/162

DTG + ABC/3TC

242

87.19

34

390a

4.49a

65/79

298.2 (SD:199.95)

222/242

83/242

36/242

34/242

DTG + TDF/FTC

129/163

GS-236-0102 [18]

EFV + TDF/FTC

352

89.77

38

382 (170.2)

4.78 (0.6)

287/352

273

61/352

EVG/c + TDF/FTC

348

88.22

38

391 (188.6)

4.73 (0.6)

293/348

295

53/348

GS-US-380-1489 [19]

BIC + TAF/FTC

314

90.76

31

443a

4.42a

276/314

287 (SD:207)

292/314

89/314

36/314

36/314

DTG + ABC/3TC

315

89.52

32

450a

4.51a

283/315

288 (SD: 247)

302/315

127/315

39/315

31/315

GS-US-380-1490 [20]

BIC + TAF/FTC

320

87.50

33

440a

4.43a

269/320

237 (SD:204)

283/320

64/320

55/320

48/320

DTG + TAF/FTC

325

88.62

34

441a

4.45a

281/325

281 (SD:209)

288/325

92/325

33/325

36/325

SINGLE (CSR) [21]

DTG + ABC/3TC

414

83.82

36

334.5a

4.67a

332/414

325.3 (SE:10.46)

376/414

184/414

44/414

72/414

EFV + TDF/FTC

419

84.96

35

339a

4.7a

303/419

281.4 (SE:10.87)

394/419

282/419

51/419

109/419

SPRING-2 (CSR) [22]

DTG + ABC/3TC

411

84.67

37

359a

4.52a

125/169

292.2 (SD:195.70)

349/411

124/411

41/411

62/411

DTG + TDF/FTC

207/242

RAL + ABC/3TC

411

86.37

35

362a

4.58a

124/164

286.2 (SD:192.45)

349/411

121/411

48/411

79/411

RAL + TDF/FTC

190/247

STaR (GS-US-264-0110)

[23]

EFV + TDF/FTC

392

92.86

35

385 (187)

4.8 (0.6)

284/392

259 (SD:191)

368/392b

102/392

RPV + TDF/FTC

394

92.89

37

396 (180)

4.8 (0.7)

307/394

278 (SD:189)

362/394b

78/394

STARMRK [24]

EFV + TDF/FTC

282

81.91

36.9

217.4 (133.6)

5 (0.6)

223/282

224.8

275/282

220/282

34/282

50/282

RAL + TDF/FTC

281

80.78

37.6

218.9 (124.2)

5.0 (0.6)

228/281

239.6

266/281

132/281

40/281

36/281

934 study [25]

EFV + 3TC/ZDV

254

87.01

37

241a

5.0a

237 (SD: 136.4)

180/254

EFV + TDF/FTC

255

85.88

36

233a

5.0a

270 (SD: 147.5)

185/257

ABCDE study [26]

EFV + ABC/3TC

115

74.8

38.4

203 (167)

4.94 (0.60)

70/115

263

40/115

EFV + 3TC/d4T

122

78.7

38.5

223 (177)

4.92 (0.57)

58/122

294

59/122

ACTG A5142 [27]

EFV + CHOICE

250

81.20

39

195

4.8

158/178

230

LPV/r + CHOICE

253

76.68

37

190

4.8

136/177

287

ACTG A5202 [28] (Clinicaltrials.gov)

ATV/r + ABC/3TC

463

83.80

38

236a

4.7 (0.7)

250.3a

141/463

ATV/r + TDF/FTC

465

83.23

38.9

224a

4.7 (0.7)

251.5a

123/465

EFV + ABC/3TC

465

78.92

38.4

225a

4.7 (0.7)

250.5a

141/465

EFV + TDF/FTC

464

84.70

38.2

234a

4.7 (0.7)

220.5a

121/464

ARTEMIS [29]

DRV/r + TDF/FTC

343

69.68

36

228a

7.1a

271/343

171a

34/343

59/343

LPV/r + TDF/FTC

346

69.65

35

218a

6.2a

246/346

188a

55/346

81/346

ASSERT [30]

EFV + TDF/FTC

193

79.79

36

230a

5.12a

76/128

220a

59/193

EFV + ABC/3TC

192

82.81

38

240a

5.01a

57/112

235a

77/192

ATADAR [31]

ATV/r + TDF/FTC

90

86.67

35

328 (205)

4.8 (0.7)

284 (SD:219)

24/90

DRV/r + TDF/FTC

88

88.64

37

341 (171)

4.8 (0.8)

298 (SD: 182)

7/88

CASTLE [32]

ATV/r + TDF/FTC

440

68.64

34

205

5.01

308/440

268

355/441

61/441

72/438

LPV/r + TDF/FTC

443

68.62

36

204

4.96

281/443

290

370/437

48/437

95/440

GS-236-0103 [33]

ATV/r + TDF/FTC

355

89.01

39

366a

4.8 (0.62)

292/355

261

50/355

55/355

EVG/c + TDF/FTC

353

91.78

38

351a

4.8 (0.61)

294/353

256

34/353

49/353

HEAT ([34], clinicaltrials.gov)

LPV/r + ABC/3TC

343

83.97

38

214a

4.903a

206/343

250a

274/343

42/343

109/343

LPV/r + TDF/FTC

345

80.00

38

193a

4.844a

200/345

246.5a

276/345

45/345

124/345

  1. a Median was used instead of mean
  2. b Reported as treatment emergent adverse events, assumed to be equivalent to other reported AEs